L-Arginine
since 1983
L-Arginine: A free-form Amino Acid
Pinoneer in L-Arginine Research since 1983
Significance of L-Arginine Amino Acid:
#1. Modulation of Sickle Cell Amenia & Thalassemia​
​
#2 Serve as Substrate for Nitric Oxide (NO) Production
​
#3. Acts as a Cardioprotective, Hepatoprotective and Immunomodulatory Agent in Humans​
​
#4 Crosses the Blood-Brain Barrier (BBB) as a Zwitterion
​
#5 Growth Hormone, Testosterone, Anti-aging & IGF
​
#6 Reduces Blood Pressure and the Risk of Heart Disease
United Nations General Assembly World Sickle Cell Day- New York
Every year on June 19, the global sickle cell community unites to celebrate World Sickle Cell Day. For the sickle cell community, this day holds much significance. Also known as World Sickle Cell Awareness Day, this day is observed internationally to increase much-needed education and awareness of a disease that affects millions of people around the globe.
In response, in 2008, the United Nations (UN) General Assembly created a resolution that formally recognized SCD as a public health problem. They declared SCD as “one of the most lethal genetic disorders” and “one of the world’s foremost genetic diseases.” The UN’s resolution served to increase the public’s awareness of SCD and its cure at a national and international level. The resolution was also created to improve the quality of life for patients with SCD worldwide and to observe June 19 as World Sickle Cell Day to continue raising awareness.​
Origin and History​
​
In 2006, the World Health Organization (WHO) recognized sickle cell disease (SCD) as a global health problem. Just one year earlier, the African Union and the United Nations Educational, Scientific, and Cultural Organization (UNESCO) had also recognized the disease as a global health problem, thanks to the advocacy of the Sickle Cell Disease International Organization (SCDIO), the support of the Republic of Congo and the Republic of Senegal, and the commitment in the scientific world. Their efforts brought to light how SCD was and is a heritable blood disorder with devastating effects.
​
June 19, 2009 was the first date that World Sickle Cell Day was celebrated.
Madame Antoinette Sassou Nguesso, First Lady of the Republic of Congo, and Madame Viviane Wade, First Lady of Senegal, joined forces to help establish a centre in Brazzaville, the Congolese capital, to study the disease, raise awareness, and bring scientists and medical professionals together to discuss prevention, care, and treatment. Howard University President Wayne A. I. Frederick pledged to develop and strengthen collaborations between the Howard Center for Sickle Cell Disease and the newly established National Sickle Cell Disease Center of Brazzaville, Congo. Madame Sassou Nguesso’s endeavors with UNESCO, as President of the Congo Assistance Foundation, and as a sponsor of SCDIO in advocacy of raising the awareness of SCD in the Congo and globally have continued to advance the collective work of OILD. She received the WHO Director-General’s Health Leaders Recognition to celebrate her contribution to the control of sickle cell anemia.
United Nations General Assembly World Sickle Cell Day
Researchers- Speakers at the United Nations World Sickle Cell Day
​
ALL NATIONS OF THE WORLD THAT ARE MEMBERS OF THE
UNITED NATIONS WERE REPRESENTED AT THE WORLD SICKLE CELL DAY JUNE 19TH 2009. THESE INCLUDE:
NIGERIAN MEMBERS OF THE SICKLE CELL FOUNDATION OF NIGERIA: HOPE ALIVE SICKLE CELL ASSOCIATION OF ABEO KUTA, OGUN STATE
PERMANENT MEMBER OF THE REPUBLIC OF CONGO TO THE UNITED NATIONS (NEW YORK)
SECRETARY GENERAL OF THE UNITED NATIONS
PRESIDENT OF THE U.N. GENERAL ASSEMBLY
WHO & UNICEF - PRESIDENT OF OILD
FIRST LADY OF THE CONGO
RESEARCHERS & PROFESSORS PRESENTING:
FRANCE, INDIA, BRAZIL, U.S., CONGO, AFRICAN NATIONS,
SICKLE CELL & THALASSEMIA PATIENTS NETWORK, SENEGAL, FIRST LADIES & MINISTERS OF AFRICAN COUNTRIWORLD HEALTH ORGANIZATION, RESEARCH SCIENTISTS FROM AROUND THE WORLD
ROUND TABLE MODERATORS:
DOCTOR LEON TSHILOLO (CONGO RDC)
TERESA GINGER DAVIS (USA)
​
SPEAKERS at the ROUND TABLE:
Representatives of the United Nations
First Ladies & Ministers of Health
Selected Research Scientists
JOHNS HOPKINS SCHOOL OF MEDICINE
June 19, 2009 marks the first annual World Sickle Cell Disease Day. Prompted by a United Nations resolution calling for the recognition of sickle cell anemia as a public health problem, World Sickle Cell Disease Day was established to promote awareness of this genetic disease that affects millions globally. Natalie Wood-Wright, associate director of public affairs for the Johns Hopkins Bloomberg School of Public Health discussed the importance of sickle cell disease awareness with Carlton Haywood associate faculty at the Johns Hopkins Berman Institute and assistant professor of medicine at the Johns Hopkins School of Medicine. He was diagnosed with sickle cell disease as a child and serves as an advocate for sickle cell education and policy change.
BY INVITATION OF TERESA G. DAVIS, UNITED NATIONS SICKLE DAY ROUND TABLE MODERATOR: DR. ANN DE WEES ALLEN, Medical & Clinical researcher with research partners esteemed DR. RANDALL MAXEY, MD, PhD, President of the National Medical Association & JOHNS HOPKINS genetic researchers. TOPIC: Dr. Allen’s patent and long-term research on L-Arginine as a modulator of Sickle Cell & Thalassemia, demonstrating that L-Arginine can exert beneficial effects in patients with Sickle Cell Disease in the crisis & steady-states of the disease. Dr. Allen’s Patent on L-Arginine was designed and formulated to serve as a substrate for Nitric Oxide (NO) production with special utilization in mountain
climbers at Mt. Kilimanjaro in Tanzania Africa (with a summit of 19,340 feet) who require higher levels than normal of Nitric Oxide. Her mountain climbing clients carried Dr. Allen’s L-Arginine formula, designed to increase levels of NO metabolites, in their climb of the tallest summits in the world, making World Records. Additionally, L-Arginine (in a safeformula without L-Lysine) acts as a cardioprotective, hepatoprotective and immunomodulatory agent in humans. Dr. Allen’s Patent on L-Arginine has already generated over $1 Billion dollars globally. Dr. Allen’s Patent on L-Arginine was the first to demonstrate that it crossed the blood-Brain Barrier (BBB) as a Zwitterion. Her Patented Core Vector Compound was used safely in thousands of humans over decades of use. Dr. Allen Core Vector Compound holds GRAS STATUS.
Hope Alive Sickle Cell Association of Abeo Kuta, Ogun State: A Registered Member of the Sickle Cell Foundation of Nigeria:
Researchers at Duke University and Howard Hughes Medical Center (HHMC) discovered one of the keys to the cause of pain in Sickle Cell disease. Their findings were reported in the Jan 31, 2005 Proceedings of the National Academy of Sciences.
The key was Nitric Oxide, a signaling molecule. Their research noted that the degree of Nitric Oxide deficiency directly correlated with symptom severity.
The Duke University/HHMC study found that the less Nitric Oxide produced, the greater the pain in Sickle Cell anemia patients.
In 1998 the Nobel Prize in Medicine was awarded to researchers in Nitric Oxide, which is produced by L-arginine in the body.
The world’s leading researcher in L-Arginine is Dr. Ann de Wees Allen, who has spent decades researching the free-form amino acid L-Arginine, and her research has led to some breakthrough discoveries.
Columbia University refers to L-Arginine as the “Magic Bullet” for the cardiovascular system.
To be effective and safe, L-Arginine must utilize a low-glycemic method. Through much research and development, Dr. Allen determined that an L-Arginine molecule must be attached to a glycoside from plants which will allow L-Arginine to cross the proper barriers. Dr. Allen formulated a unique Low glycemic product called ProArgi-9 that was granted a Patent.
Under FDA and FTC regulations, and with the assistance of her attorney, Peter Barton Hutt, Director of the Food & Drug Association (FDA), and author of CFR 21 Guidelines, Dr. Allen was able to clinically prove that she could legally make of 15 claims, with the 14th claim as “Helps produce Nitric Oxide”.
Prominent medical researchers, from Johns Hopkins and NIH, as well as the President of the National Medical Association, Dr. Randall Maxey, MD, PhD, and President of NMA Research Foundation for Ethnic-Related Diseases, with expert experience in genetic polymorphisms in African Americans, the researchers contacted Dr. Allen with the goal of forming a team specializing in the utility of L-Arginine in the treatment of Sickle Cell disease.
They named the team CodeBreaker. After 5 years of hard work and research validation, the CodeBreaker team went public and licensed Dr. Allen’s L-Arginine Patent to a very large Global company, which hired the team to lecture globally on their breakthrough findings related to Sickle Cell and L-arginine.
The CodeBreaker team lectured all across Asis, including lectures at the United Nations General Assembly featuring World Sickle Cell Day in 2009, and at the Tokyo Convention Center to thousands of people, and physicians specializing in Asian Thalassemia. In Asia, Sickle Cell disease is called Thalassemia.
The CodeBreaker team was responsible for generation a $Billion dollars in sales of Dr. Allen’s L-Arginine patented Nitric Oxide formula.
This Press Release was presented and authored by:
HOPE ALIVE - SICKLE CELL ASSOCIATION OF ABEO KUTA, OGUN STATE: A REGISTERED MEMBER OF THE SICKLE CELL FOUNDATION OF NIGERIA:
A Live Interview with Dr. Ann de Wees Allen from the United Nations General Assembly
From the Black Preaching Network: Darwin Ali-
Medical Professionals in the News
United Nations Interviewer: Congratulations on your presentation today to the United Nations at the United Nations General Assembly, regarding your research on L-Arginine and Sickle Cell, it is indeed a pleasure to speak with you.
​
Dr. Allen person, as I have followed your research on L-Arginine and Sickle Cell and had the pleasure of attending your scientific lectures in many of the countries in Asia when you spoke in Hong Kong, Singapore, Thailand, and Japan at the Tokyo Convention Center.
Dr. Allen: Thank you very much. It was a great honor to be invited to the United Nations General Assembly to present the current research on L-Arginine, Sickle Cell and other global genetic polymorphisms.
United Nations Interviewer: Your research partners from the National Institutes of Health (NIH), Johns Hopkins School of Medicine, National Human Genome Research Institute, and the National Medical Association, are here with you today at the United Nations.
Dr. Allen: Yes, we have worked for five years together on this important project, including my dear friend and co-researcher Dr. Randall Maxey, MD, PhD, President of the National America
Quotations from Dr. Allen’s research partners at the United Nations:
“Dr. Allen is a pioneer in the area of L-arginine research and began her study of the amino acid L-Arginine in 1983, years ahead of any other scientists.
Dr. Allen is solely credited with the discovery that L-Arginine is a Blind Amino Acid® and that without a Blind Amino Acid Rider®, L-Arginine can be quite dangerous in humans.
Dr. Allen’s research was validated by the Journal of the American Medical Association (JAMA) and the Johns Hopkins Trial on L-Arginine. For this research, Dr. Allen received a Federal Patent.
Dr. Allen’s research on L-Arginine covers Growth Hormone, Testosterone, Anti-Aging, IGF, and nitric oxide (NO). Arginine is one of the twenty amino acids that are the building blocks of protein, and serves as the precursor to the production of nitric oxide (NO) in the body. NO circulates in the bloodstream and plays an important role in relaxation of the blood vessels, contributing to reducing blood pressure and the risk of heart disease.
Considered the leading L-Arginine researcher in the world, Dr. Allen’s L-Arginine discoveries and Patents revolutionized the safe long-term use of arginine in humans.
These Patents will forever change the face of genetic poylmorphisms, such as Sickle Cell in Africa and African/Americans and Thalassemia, the most widespread genetic problem in Asia.”
Dr. Allen: We have worked very hard together for the past five years, and today it all became
worth it. It’s astounding to stand before all of the countries represented here, and humbling.
United Nations Interviewer: In your lecture to the Representatives of the United Nations, you discussed methodologies for using L-Arginine in the treatment of genetic polymorphisms, including Sickle Cell and Thalassemia, particularly in children worldwide.
Is it true that you have offered to provide the use of those patents Pro-Bono to every country represented here at the United Nations?
Dr. Allen: Absolutely – because no scientist should own or control any important
breakthrough that can help children worldwide. After 3 decades as a Clinical Researcher for the largest food companies in the world, specializing in the Glycemic Index, L-Arginine, obesity, diabetes, anti-aging, and global health, I now want to focus on bringing future-science to the public. The best way to accomplish this goal is to align with like-minded companies.
United Nations Interviewer: Your patents and research have generated over $ 1 Billion dollars globally and were even featured on the front page of the Wall Street journal. What new areas of research are you involved in now?
Dr. Allen: Scientists can lead the global force in New Science, such as Sickle Cell, Thalassemia (in Asia), Anti-Aging, and new approaches to childhood and adult obesity and diabetes. Let’s face it, the standard approach to these ailments is NOT working, and we need to find solutions that get results.
The answers are within our reach, and those solutions need to be exploited and expanded for the good of human health everywhere on the globe.
United Nations Interviewer: Thanks very much Dr. Allen for the time you have spent with me today.